There is a high prevalence of psychotic-like experiences in nonclinical patient cohorts from Brazil. This study aimed to test whether personality dimensions, as well as schizotypy, are important predictors of quality of life (QoL) in individuals with psychotic experiences (PE). Method: 115 participants were recruited from Spiritist Centers in Brazil. At the 1-year follow up, 90 participants (78%) were reassessed. Instruments were the SCID-I (Structured Clinical Interview for DSM-IV), TCI-R 140 (Revised Temperament and Character Inventory), OLIFE-R (Oxford-Liverpool Inventory of Feelings and Experiences), and WHOQOL-BREF (World Health Organization QoL Instrument). Results: Mean age (±SD) was 36.8 (±12.5) years; 70% were female. Participants reported 74.4% of PE at time 1 and 72.3% at time 2. At time 1, temperament and character explained 47% of the psychological QoL variance; self-directedness was the strongest predictor of higher QoL, while harm avoidance and introverted anhedonia predicted worse QoL. At the 1-year follow-up, self-directedness remained the most important predictor of psychological QoL. Conclusion: Individuals reporting PE can show psychological QoL when they are high on self-directedness. Those with high levels of introverted anhedonia and cognitive disorganization can have a lower QoL and may be at risk for mental health problems.

1.
Tandon R, Gaebel W, Barch DM, Bustillo J, Gur RE, Heckers S, et al: Definition and description of schizophrenia in the DSM-5. Schizophr Res 2013;150:3-10.
2.
Peters E, Ward T, Jackson M, Morgan C, Charalambides M, McGuire P, et al: Clinical, socio-demographic and psychological characteristics in individuals with persistent psychotic experiences with and without a “need for care”. World Psychiatry 2016;15:41-52.
3.
Holt N, Simmonds-Moore C, Moore S, Holt N, Simmonds-Moore C, Moore S: Benign schizotypy: investigating differences between clusters of schizotype on paranormal belief, creativity, intelligence and mental health; in Sherwood S (ed): Proceedings of Presented Papers: The Parapsychological Association 51st Annual Convention. Columbus, Parapsychological Association, 2008, pp 82-96, http://eprints.uwe.ac.uk/15726/.
4.
Alminhana LO, Farias M, Claridge G, Cloninger CR, Moreira-Almeida A: How to tell a happy from an unhappy schizotype: personality factors and mental health outcomes in individuals with psychotic experiences. Rev Bras Psiquiatr 2016, Epub ahead of print.
5.
Horan WP, Blanchard JJ, Clark LA, Green MF: Affective traits in schizophrenia and schizotypy. Schizophr Bull 2008;34:856-874.
6.
Ritsner MS, Arbitman M, Lisker A: Anhedonia is an important factor of health-related quality-of-life deficit in schizophrenia and schizoaffective disorder. J Nerv Ment Dis 2011;199:845-853.
7.
Cloninger CR: Feeling Good: The Science of Well-Being, ed 1. Oxford, Oxford University Press, 2004, p 400.
8.
Masthoff ED, Trompenaars FJ, Van Heck GL, Hodiamont PP, De Vries J: Quality of life and psychopathology: investigations into their relationship. Aust NZ J Psychiatry 2006;40:333-340.
9.
Margetić BA, Jakovljević M, Ivanec D, Margetić B: Temperament, character, and quality of life in patients with schizophrenia and their first-degree relatives. Compr Psychiatry 2011;52:425-430.
10.
Cohen AS, Davis TE III: Quality of life across the schizotypy spectrum: findings from a large nonclinical adult sample. Compr Psychiatry 2009;50:408-414.
11.
Moreira-Almeida A, Lotufo Neto F, Greyson B: Dissociative and psychotic experiences in Brazilian spiritist mediums. Psychother Psychosom 2007;76:57-58.
12.
Del-Ben CM, Vilela JAA, de S Crippa JA, Hallak JEC, Labate CM, Zuardi AW: Reliability of the Structured Clinical Interview for DSM-IV - Clinical Version translated into Portuguese. Rev Bras Psiquiatr 2001;23:156-159.
13.
Goncalves DM, Cloninger CR: Validation and normative studies of the Brazilian Portuguese and American versions of the Temperament and Character Inventory - Revised (TCI-R). J Affect Disord 2010;124:126-133.
14.
Mason O, Linney Y, Claridge G: Short scales for measuring schizotypy. Schizophr Res 2005;78:293-296.
15.
Fleck MP, Louzada S, Xavier M, Chachamovich E, Vieira G, Santos L, et al: Application of the Portuguese version of the abbreviated instrument of quality life WHOQOL-bref. Rev Saúde Pública 2000;34:178-183.
16.
Gonzalez-Torres MA, Inchausti L, Ibáñez B, Aristegui M, Fernández-Rivas A, Ruiz E, et al: Temperament and character dimensions in patients with schizophrenia, relatives, and controls. J Nerv Ment Dis 2009;197:514-519.
17.
Hori H, Teraishi T, Sasayama D, Matsuo J, Kinoshita Y, Ota M, et al: A latent profile analysis of schizotypy, temperament and character in a nonclinical population: association with neurocognition. J Psychiatr Res 2014;48:56-64.
18.
Lin A, Wigman JTW, Nelson B, Wood SJ, Vollebergh WAM, van Os J, et al: Follow-up factor structure of schizotypy and its clinical associations in a help-seeking sample meeting ultra-high risk for psychosis criteria at baseline. Compr Psychiatry 2013;54:173-180.
19.
Sigaudo M, Crivelli B, Castagna F, Giugiario M, Mingrone C, Montemagni C, et al: Quality of life in stable schizophrenia: the relative contributions of disorganization and cognitive dysfunction. Schizophr Res 2014;153:196-203.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.